Skip to main content
Top
Published in: Endocrine 1/2017

01-01-2017 | Original Article

Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism

Authors: Giuseppe Viccica, Filomena Cetani, Edda Vignali, Mario Miccoli, Claudio Marcocci

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

The purpose of the study was to evaluate the relationship between serum 25(OH)D and the clinical phenotype in 215 consecutive Italian Caucasian women with sporadic primary hyperparathyroidism (PHPT) not taking vitamin D supplements. The study was performed at a single Italian tertiary center. PHPT-related manifestations, serum 25(OH)D, and other parameters of calcium metabolism and bone mineral density (BMD) by DXA were recorded. Serum 25(OH)D was negatively correlated with age (r = −0.18; P = 0.006), BMI (r = −0.20; P = 0.002), PTH (r = −0.21; P = 0.001), bone-specific alkaline phosphatase (BSAP) (r = −0.27; P < 0.001), and eGFR (r = −0.22; P = 0.01), and positively with serum creatinine and 1/3 distal radius BMD (R-BMD; r = 0.17; P = 0.015). In a multivariate regression analysis, serum 25(OH)D remained significantly correlated with age (r = −0.18; P = 0.005), BMI (r = −0.23; P = 0.049), serum PTH (r = −0.01; P = 0.023), BSAP (r = −0.01; P = 0.023) and eGFR (r = −0.09; P = 0.001), but not with R-BMD. Serum 25(OHD) was higher in patients with nephrolithiasis than in those without nephrolithiasis (18.5 ± 8.8 vs. 15.6 ± 8.0 ng/ml; P = 0.029), whereas no difference was found between fractured and unfractured patients (16.8 ± 9.3 vs. 16.0 ± 7.7; P = 0.663). There was a statistically significant inverse correlation between vitamin D status [defined by quartiles of measured values as well as commonly accepted cutoffs of serum 25(OH)D] and severity of the disease, as reflected by higher PTH and BSAP, but not by meeting the latest guidelines for parathyroidectomy. In conclusion, a low vitamin D status is associated with some features reflecting a more severe biochemical and clinical phenotype of PHPT in Italian women not taking vitamin D supplements.
Appendix
Available only for authorised users
Literature
2.
4.
go back to reference J.M. Liu, N.E. Cusano, B.C. Silva, L. Zhao, X.Y. He, B. Tao, L.H. Sun, H.Y. Zhao, W.W. Fan, M.E. Romano, G. Ning, J.P. Bilezikian, Primary hyperparathyroidism: a tale of two cities revisited—New York and Shanghai. Bone. Res. 1(2), 162–169 (2013). doi:10.4248/BR201302005 CrossRefPubMedPubMedCentral J.M. Liu, N.E. Cusano, B.C. Silva, L. Zhao, X.Y. He, B. Tao, L.H. Sun, H.Y. Zhao, W.W. Fan, M.E. Romano, G. Ning, J.P. Bilezikian, Primary hyperparathyroidism: a tale of two cities revisited—New York and Shanghai. Bone. Res. 1(2), 162–169 (2013). doi:10.​4248/​BR201302005 CrossRefPubMedPubMedCentral
5.
go back to reference S. Varshney, S.K. Bhadada, U.N. Saikia, N. Sachdeva, A. Behera, A.K. Arya, S. Sharma, A. Bhansali, A. Mithal, S.D. Rao, Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur. J. Endocrinol. 169(1), 109–116 (2013). doi:10.1530/EJE-13-0085 CrossRefPubMed S. Varshney, S.K. Bhadada, U.N. Saikia, N. Sachdeva, A. Behera, A.K. Arya, S. Sharma, A. Bhansali, A. Mithal, S.D. Rao, Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur. J. Endocrinol. 169(1), 109–116 (2013). doi:10.​1530/​EJE-13-0085 CrossRefPubMed
6.
go back to reference A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 dietary reference intakes for calcium and vitamin D: what dietetics practitioners need to know. J. Am. Diet. Assoc. 111(4), 524–527 (2011). doi:10.1016/j.jada.2011.01.004 CrossRefPubMed A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 dietary reference intakes for calcium and vitamin D: what dietetics practitioners need to know. J. Am. Diet. Assoc. 111(4), 524–527 (2011). doi:10.​1016/​j.​jada.​2011.​01.​004 CrossRefPubMed
7.
go back to reference C. Marcocci, J. Bollerslev, A.A. Khan, D.M. Shoback, Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 99(10), 3607–3618 (2014). doi:10.1210/jc.2014-1417 CrossRefPubMed C. Marcocci, J. Bollerslev, A.A. Khan, D.M. Shoback, Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 99(10), 3607–3618 (2014). doi:10.​1210/​jc.​2014-1417 CrossRefPubMed
9.
go back to reference D.S. Rao, M. Honasoge, G.W. Divine, E.R. Phillips, M.W. Lee, M.R. Ansari, G.B. Talpos, A.M. Parfitt, Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J. Clin. Endocrinol. Metab. 85(3), 1054–1058 (2000). doi:10.1210/jcem.85.3.6440 PubMed D.S. Rao, M. Honasoge, G.W. Divine, E.R. Phillips, M.W. Lee, M.R. Ansari, G.B. Talpos, A.M. Parfitt, Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J. Clin. Endocrinol. Metab. 85(3), 1054–1058 (2000). doi:10.​1210/​jcem.​85.​3.​6440 PubMed
10.
go back to reference B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde, Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin. Endocrinol. 63(5), 506–513 (2005). doi:10.1111/j.1365-2265.2005.02371.x CrossRef B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde, Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin. Endocrinol. 63(5), 506–513 (2005). doi:10.​1111/​j.​1365-2265.​2005.​02371.​x CrossRef
11.
go back to reference P. Boudou, F. Ibrahim, C. Cormier, E. Sarfati, J.C. Souberbielle, A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J. Endocrinol. Invest. 29(6), 511–515 (2006). doi:10.1007/BF03344140 CrossRefPubMed P. Boudou, F. Ibrahim, C. Cormier, E. Sarfati, J.C. Souberbielle, A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J. Endocrinol. Invest. 29(6), 511–515 (2006). doi:10.​1007/​BF03344140 CrossRefPubMed
12.
go back to reference S.J. Silverberg, E. Shane, D.W. Dempster, J.P. Bilezikian, The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am. J. Med. 107(6), 561–567 (1999)CrossRefPubMed S.J. Silverberg, E. Shane, D.W. Dempster, J.P. Bilezikian, The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am. J. Med. 107(6), 561–567 (1999)CrossRefPubMed
15.
go back to reference M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, M.H. Murad, C.M. Weaver, S. Endocrine, Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(7), 1911–1930 (2011). doi:10.1210/jc.2011-0385 CrossRefPubMed M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, M.H. Murad, C.M. Weaver, S. Endocrine, Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(7), 1911–1930 (2011). doi:10.​1210/​jc.​2011-0385 CrossRefPubMed
16.
go back to reference J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts Jr, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99(10), 3561–3569 (2014). doi:10.1210/jc.2014-1413 CrossRefPubMed J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts Jr, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99(10), 3561–3569 (2014). doi:10.​1210/​jc.​2014-1413 CrossRefPubMed
17.
go back to reference M.D. Walker, E. Cong, J.A. Lee, A. Kepley, C. Zhang, D.J. McMahon, S.J. Silverberg, Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J. Clin. Endocrinol. Metab. 100(9), 3443–3451 (2015). doi:10.1210/jc.2015-2022 CrossRefPubMedPubMedCentral M.D. Walker, E. Cong, J.A. Lee, A. Kepley, C. Zhang, D.J. McMahon, S.J. Silverberg, Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J. Clin. Endocrinol. Metab. 100(9), 3443–3451 (2015). doi:10.​1210/​jc.​2015-2022 CrossRefPubMedPubMedCentral
18.
go back to reference F. Cetani, E. Pardi, S. Borsari, M. Tonacchera, E. Morabito, A. Pinchera, C. Marcocci, G. Dipollina, Two Italian kindreds with familial hypocalciuric hypercalcaemia caused by loss-of-function mutations in the calcium-sensing receptor (CaR) gene: functional characterization of a novel CaR missense mutation. Clin. Endocrinol. 58(2), 199–206 (2003)CrossRef F. Cetani, E. Pardi, S. Borsari, M. Tonacchera, E. Morabito, A. Pinchera, C. Marcocci, G. Dipollina, Two Italian kindreds with familial hypocalciuric hypercalcaemia caused by loss-of-function mutations in the calcium-sensing receptor (CaR) gene: functional characterization of a novel CaR missense mutation. Clin. Endocrinol. 58(2), 199–206 (2003)CrossRef
19.
go back to reference A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal Disease study group. Ann. Intern. Med. 130(6), 461–470 (1999)CrossRefPubMed A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal Disease study group. Ann. Intern. Med. 130(6), 461–470 (1999)CrossRefPubMed
20.
go back to reference E.M. Lewiecki, C.M. Gordon, S. Baim, M.B. Leonard, N.J. Bishop, M.L. Bianchi, H.J. Kalkwarf, C.B. Langman, H. Plotkin, F. Rauch, B.S. Zemel, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, S. Silverman, International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 43(6), 1115–1121 (2008). doi:10.1016/j.bone.2008.08.106 CrossRefPubMed E.M. Lewiecki, C.M. Gordon, S. Baim, M.B. Leonard, N.J. Bishop, M.L. Bianchi, H.J. Kalkwarf, C.B. Langman, H. Plotkin, F. Rauch, B.S. Zemel, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, S. Silverman, International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 43(6), 1115–1121 (2008). doi:10.​1016/​j.​bone.​2008.​08.​106 CrossRefPubMed
21.
go back to reference E. Vignali, G. Viccica, D. Diacinti, F. Cetani, L. Cianferotti, E. Ambrogini, C. Banti, R. Del Fiacco, J.P. Bilezikian, A. Pinchera, C. Marcocci, Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94(7), 2306–2312 (2009). doi:10.1210/jc.2008-2006 CrossRefPubMedPubMedCentral E. Vignali, G. Viccica, D. Diacinti, F. Cetani, L. Cianferotti, E. Ambrogini, C. Banti, R. Del Fiacco, J.P. Bilezikian, A. Pinchera, C. Marcocci, Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94(7), 2306–2312 (2009). doi:10.​1210/​jc.​2008-2006 CrossRefPubMedPubMedCentral
22.
go back to reference M. Peacock, Primary hyperparathyroidism and the kidney. The parathyroids. Basic and clinical concepts. (Elsevier Inc., London, 2015) M. Peacock, Primary hyperparathyroidism and the kidney. The parathyroids. Basic and clinical concepts. (Elsevier Inc., London, 2015)
25.
go back to reference A. D’Angelo, M.G. Lodetti, S. Giannini, R. Castrignano, M. Al Awady, L. Malvasi, A. Fabris, G. Maschio, Hyperparathyroidism: cause or consequence of recurrent calcium nephrolithiasis? Miner. Electrolyte. Metab. 18(6), 359–364 (1992)PubMed A. D’Angelo, M.G. Lodetti, S. Giannini, R. Castrignano, M. Al Awady, L. Malvasi, A. Fabris, G. Maschio, Hyperparathyroidism: cause or consequence of recurrent calcium nephrolithiasis? Miner. Electrolyte. Metab. 18(6), 359–364 (1992)PubMed
26.
go back to reference C.V. Odvina, K. Sakhaee, H.J. Heller, R.D. Peterson, J.R. Poindexter, P.K. Padalino, C.Y. Pak, Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol. Res. 35(3), 123–128 (2007). doi:10.1007/s00240-007-0096-2 CrossRefPubMed C.V. Odvina, K. Sakhaee, H.J. Heller, R.D. Peterson, J.R. Poindexter, P.K. Padalino, C.Y. Pak, Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol. Res. 35(3), 123–128 (2007). doi:10.​1007/​s00240-007-0096-2 CrossRefPubMed
27.
go back to reference S.J. Silverberg, E. Shane, T.P. Jacobs, E.S. Siris, F. Gartenberg, D. Seldin, T.L. Clemens, J.P. Bilezikian, Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am. J. Med. 89(3), 327–334 (1990)CrossRefPubMed S.J. Silverberg, E. Shane, T.P. Jacobs, E.S. Siris, F. Gartenberg, D. Seldin, T.L. Clemens, J.P. Bilezikian, Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am. J. Med. 89(3), 327–334 (1990)CrossRefPubMed
28.
go back to reference F. Tassone, L. Gianotti, C. Baffoni, G. Visconti, M. Pellegrino, S. Cassibba, C.G. Croce, G. Magro, F. Cesario, R. Attanasio, G. Borretta, Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin. Endocrinol. 79(6), 784–790 (2013). doi:10.1111/cen.12210 CrossRef F. Tassone, L. Gianotti, C. Baffoni, G. Visconti, M. Pellegrino, S. Cassibba, C.G. Croce, G. Magro, F. Cesario, R. Attanasio, G. Borretta, Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin. Endocrinol. 79(6), 784–790 (2013). doi:10.​1111/​cen.​12210 CrossRef
29.
go back to reference V. Carnevale, G. Manfredi, E. Romagnoli, S. De Geronimo, F. Paglia, J. Pepe, A. Scillitani, E. D’Erasmo, S. Minisola, Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin. Endocrinol. 60(1), 81–86 (2004)CrossRef V. Carnevale, G. Manfredi, E. Romagnoli, S. De Geronimo, F. Paglia, J. Pepe, A. Scillitani, E. D’Erasmo, S. Minisola, Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin. Endocrinol. 60(1), 81–86 (2004)CrossRef
31.
go back to reference B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde, Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol. 155(2), 237–244 (2006). doi:10.1530/eje.1.02197 CrossRefPubMed B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde, Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol. 155(2), 237–244 (2006). doi:10.​1530/​eje.​1.​02197 CrossRefPubMed
32.
go back to reference H. Raef, S. Ingemansson, S. Sobhi, A. Sultan, M. Ahmed, M. Chaudhry, The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J. Endocrinol. Invest. 27(9), 807–812 (2004). doi:10.1007/BF03346273 CrossRefPubMed H. Raef, S. Ingemansson, S. Sobhi, A. Sultan, M. Ahmed, M. Chaudhry, The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J. Endocrinol. Invest. 27(9), 807–812 (2004). doi:10.​1007/​BF03346273 CrossRefPubMed
33.
go back to reference N. Ozbey, Y. Erbil, E. Ademoglu, S. Ozarmagan, U. Barbaros, A. Bozbora, Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World. J. Surg. 30(3), 321–326 (2006). doi:10.1007/s00268-005-0239-y CrossRefPubMed N. Ozbey, Y. Erbil, E. Ademoglu, S. Ozarmagan, U. Barbaros, A. Bozbora, Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World. J. Surg. 30(3), 321–326 (2006). doi:10.​1007/​s00268-005-0239-y CrossRefPubMed
35.
36.
go back to reference Y. Inoue, H. Kaji, I. Hisa, T. Tobimatsu, J. Naito, M.F. Iu, T. Sugimoto, K. Chihara, Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr. J. 55(1), 57–65 (2008)CrossRefPubMed Y. Inoue, H. Kaji, I. Hisa, T. Tobimatsu, J. Naito, M.F. Iu, T. Sugimoto, K. Chihara, Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr. J. 55(1), 57–65 (2008)CrossRefPubMed
37.
go back to reference D.S. Rao, G. Agarwal, G.B. Talpos, E.R. Phillips, F. Bandeira, S.K. Mishra, A. Mithal, Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J. Bone. Miner. Res. 17(Suppl 2), N75–80 (2002)PubMed D.S. Rao, G. Agarwal, G.B. Talpos, E.R. Phillips, F. Bandeira, S.K. Mishra, A. Mithal, Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J. Bone. Miner. Res. 17(Suppl 2), N75–80 (2002)PubMed
38.
go back to reference P. Farahnak, G. Larfars, M. Sten-&&&&&&&Linder, I.L. Nilsson, Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J. Clin. Endocrinol. Metab. 96(7), 2112–2118 (2011). doi:10.1210/jc.2011-0238 CrossRefPubMed P. Farahnak, G. Larfars, M. Sten-&&&&&&&Linder, I.L. Nilsson, Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J. Clin. Endocrinol. Metab. 96(7), 2112–2118 (2011). doi:10.​1210/​jc.​2011-0238 CrossRefPubMed
39.
go back to reference A. Grey, J. Lucas, A. Horne, G. Gamble, J.S. Davidson, I.R. Reid, Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab. 90(4), 2122–2126 (2005). doi:10.1210/jc.2004-1772 CrossRefPubMed A. Grey, J. Lucas, A. Horne, G. Gamble, J.S. Davidson, I.R. Reid, Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab. 90(4), 2122–2126 (2005). doi:10.​1210/​jc.​2004-1772 CrossRefPubMed
42.
go back to reference L. Rolighed, L. Rejnmark, T. Sikjaer, L. Heickendorff, P. Vestergaard, L. Mosekilde, P. Christiansen, Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 99(3), 1072–1080 (2014). doi:10.1210/jc.2013-3978 CrossRefPubMed L. Rolighed, L. Rejnmark, T. Sikjaer, L. Heickendorff, P. Vestergaard, L. Mosekilde, P. Christiansen, Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 99(3), 1072–1080 (2014). doi:10.​1210/​jc.​2013-3978 CrossRefPubMed
Metadata
Title
Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism
Authors
Giuseppe Viccica
Filomena Cetani
Edda Vignali
Mario Miccoli
Claudio Marcocci
Publication date
01-01-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0931-8

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.